StreetInsider.com News Articles

Atea Pharmaceuticals (AVIR) PT Raised to $7 at Morgan Stanley

Thu, 13 Aug 2026 08:08:20 -0400

Morgan Stanley analyst Matthew Harrison raised the price target on Atea Pharmaceuticals (NASDAQ: AVIR) to $7.00 (from $6.00) while maintaining a Equalweight rating.

Form 10-Q Atea Pharmaceuticals, For: Jun 30

Wed, 12 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260812/26913775.html

Form 10-Q Atea Pharmaceuticals, For: Jun 30

Wed, 12 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260812/26913775.html

Form 8-K Atea Pharmaceuticals, For: Aug 12

Wed, 12 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260812/26913093.html

Form 8-K Atea Pharmaceuticals, For: Aug 12

Wed, 12 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260812/26913093.html

Aviragen Therapeutics (AVIR) Tops Q2 EPS by 15c

Wed, 12 Aug 2026 16:14:06 -0400

Aviragen Therapeutics (NASDAQ: AVIR) reported Q2 EPS of ($0.41), $0.15 better than the analyst estimate of ($0.56).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 12 Aug 2026 16:05:00 -0400

Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV

C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027

AT-587 Phase 1 Clinical Trial Advancing for Treatment of Hepatitis E Virus (HEV)

Company Holding Conference Call Today at 4:30 pm ET

BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 12 Aug 2026 16:05:00 -0400

C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027

AT-587 Phase 1 Clinical Trial Advancing for Treatment of Hepatitis E Virus (HEV)

Company Holding Conference Call Today at 4:30 pm ET

BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 12 Aug 2026 16:05:00 -0400

C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027

AT-587 Phase 1 Clinical Trial Advancing for Treatment of Hepatitis E Virus (HEV)

Company Holding Conference Call Today at 4:30 pm ET

BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 12 Aug 2026 16:05:00 -0400

C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027

AT-587 Phase 1 Clinical Trial Advancing for Treatment of Hepatitis E Virus (HEV)

Company Holding Conference Call Today at 4:30 pm ET

BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 12 Aug 2026 16:05:00 -0400

C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027

AT-587 Phase 1 Clinical Trial Advancing for Treatment of Hepatitis E Virus (HEV)

Company Holding Conference Call Today at 4:30 pm ET

BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 12 Aug 2026 16:05:00 -0400

C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027

AT-587 Phase 1 Clinical Trial Advancing for Treatment of Hepatitis E Virus (HEV)

Company Holding Conference Call Today at 4:30 pm ET

BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 12 Aug 2026 16:05:00 -0400

C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027

AT-587 Phase 1 Clinical Trial Advancing for Treatment of Hepatitis E Virus (HEV)

Company Holding Conference Call Today at 4:30 pm ET

BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 12 Aug 2026 16:05:00 -0400

C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027

AT-587 Phase 1 Clinical Trial Advancing for Treatment of Hepatitis E Virus (HEV)

Company Holding Conference Call Today at 4:30 pm ET

BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 12 Aug 2026 16:05:00 -0400

C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027

AT-587 Phase 1 Clinical Trial Advancing for Treatment of Hepatitis E Virus (HEV)

Company Holding Conference Call Today at 4:30 pm ET

BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 12 Aug 2026 16:05:00 -0400

C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027

AT-587 Phase 1 Clinical Trial Advancing for Treatment of Hepatitis E Virus (HEV)

Company Holding Conference Call Today at 4:30 pm ET

BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 12 Aug 2026 16:05:00 -0400

C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027

AT-587 Phase 1 Clinical Trial Advancing for Treatment of Hepatitis E Virus (HEV)

Company Holding Conference Call Today at 4:30 pm ET

BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 12 Aug 2026 16:05:00 -0400

C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027

AT-587 Phase 1 Clinical Trial Advancing for Treatment of Hepatitis E Virus (HEV)

Company Holding Conference Call Today at 4:30 pm ET

BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

Wed, 05 Aug 2026 07:00:00 -0400

BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, August 12, 2026, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2026, and to provide a business update.

To access the live conference call, participants may register here. The live audio webcast of the call will be

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

Wed, 05 Aug 2026 07:00:00 -0400

To access the live conference call, participants may register here. The live audio webcast of the call will be

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

Wed, 05 Aug 2026 07:00:00 -0400

To access the live conference call, participants may register here. The live audio webcast of the call will be

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

Wed, 05 Aug 2026 07:00:00 -0400

To access the live conference call, participants may register here. The live audio webcast of the call will be

Atea Pharmaceuticals HCV drug meets phase 3 trial endpoints

Tue, 28 Jul 2026 07:00:56 -0400

Atea Pharmaceuticals (NASDAQ: AVIR) announced that its hepatitis C drug combination bemnifosbuvir/ruzasvir (BEM/RZR) met both primary and secondary endpoints in the phase 3 C-BEYOND trial conducted across approximately 120 sites in the US and Canada.

The trial enrolled 905 patients in the modified intent-to-treat population. BEM/RZR achieved a sustained virologic response (SVR) rate of 93.9% compared to 94.8% for the standard-of-care drug sofosbuvir/velpatasvir (SOF/VEL, marketed as Epclusa), meeting the prespecified statistical non-inferiority margin of 5%.

In patients without cirrhosis, BEM/RZR was administered for eight weeks versus 12 weeks for SOF/VEL, with SVR rates of 93.5% and 94.6%, respectively. In patients with cirrhosis,

Atea Pharmaceuticals HCV drug meets phase 3 trial endpoints

Tue, 28 Jul 2026 07:00:56 -0400

In patients without cirrhosis, BEM/RZR was administered for eight weeks versus 12 weeks for SOF/VEL, with SVR rates of 93.5% and 94.6%, respectively. In patients with cirrhosis,

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

Tue, 28 Jul 2026 07:00:00 -0400

Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa®), a Standard-of-Care, in First-Ever Successful Head-to-Head Trial in a Global Phase 3 Program of Hepatitis C Virus (HCV) Treatments

Results Reinforce Potential Best-in-Class Profile of BEM/RZR as a Short 8-Week Treatment for Patients Without Cirrhosis

Up to 4 Million People in the US Living with HCV, Which Can Progress to Cirrhosis, End-Stage Liver Disease and Liver Cancer if Left Untreated

BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical